Overview

LHI Technology is a manufacturer of medical cables with offices in China, Singapore, the US, and Germany. The company’s complex products are used in challenging environments to provide real time information for patients; only a handful of players globally have this capability

During our ownership, the company evolved from a business focused predominantly on blood oxygen monitoring into one offering more technically demanding and higher performance products, including ECG and ultrasound cables and cables for surgical and video endoscopy applications, including ultrasound.

Working with management, we implemented several operational improvements, including increasing the company’s technical capabilities and optimising key costs.

Highlights

• Implemented several strategies to drive growth, invested in technical capabilities, developed succession plan and optimised cost in freight and distribution
• Significantly diversified both the product range and customer base
• Numerous award wins including the GE Innovation award in 2012 for outstanding performance in quality, delivery and cost reduction
• Introduced a seasoned industry executive, Al Bautista, as Chairman

Regulatory information 
This transaction involved a recommendation of 3i Investments plc, advised by 3i Singapore.

Overview

Quintiles delivered transformational growth to become the world’s largest provider of life sciences product development and integrated healthcare services. It helps biopharmaceutical customers, as well as other healthcare customers, navigate the increasingly complex healthcare environment to improve efficiency and deliver better healthcare outcomes.

During our ownership, Quintiles expanded its commercial services into the Middle East, North Africa and East Africa, and developed numerous clinical development and joint venture partnerships. The business also expanded its Real-World & Late Phase offering through acquisitions and strategic partnerships. Quintiles has an extensive reach and has helped develop or commercialise most of the top biopharmaceutical and biologic products on the market today.

In November 2017, post 3i’s exit, Quintiles adopted the name of IQVIA

Highlights

• Completed nine acquisitions
• Near doubling of revenue from $2.8bn to $4.5bn; EBITDA grew over 250%
• Expanded the global employee base from c 20,000 to c 35,000 employees
• Listed on the NYSE in May 2013, becoming a member of the FORTUNE 500, and named in FORTUNE’s list of the “World’s Most Admired Companies”

Regulatory information 
This transaction involved a recommendation of 3i Corporation, a US wholly owned subsidiary of 3i Group. It should not be assumed that recommendations made in the future will be profitable or will equal the performance of the securities in this release. For data relating to other assets involving a past recommendation by 3i Corporation please click here.

Overview

Founded in 2000, Vedici is one of the main providers of private acute care in France. Upon 3i’s exit, it was the fourth largest provider, had c.6,000 staff and ran c.4500 beds in 35 care facilities located between Paris and southern / south-western France.

3i invested in Vedici in 2010 to support both its organic and buy-and-build growth strategies.

Highlights

• Vedici grew significantly under 3i’s ownership, increasing its market share to become the fourth largest provider of private acute care in France
• Increased the number of beds by 70% to c.4,500 and more than doubled the number of private hospitals and rehabilitation centres
• Through several sale & lease back deals, 3i helped Vedici to strengthen its balance sheet and execute organic and external growth opportunities
• 3i worked with management to restructure the group, including the set-up of a full PMO function; the overhaul of the IT systems; the creation of a central “best practices” team; the launch of several optimisation programs including “staff management best practices roll-out”; and group procurement synergies
• 3i’s Business Leaders Network helped strengthen the management team, including through the introduction of the COO, CFO and IT Director.

Regulatory information 
This transaction involved a recommendation of 3i Investments plc, advised by 3i France.

Overview

Xellia is a specialty pharmaceutical group focused on the development, manufacturing and global commercialisation of anti-infective therapies. During our ownership, Xellia transformed from a supplier of niche active pharmaceutical ingredients to a fully integrated speciality pharmaceutical company.

During our investment period, Xellia invested more than $100 million in research and development (‘R&D’) and capacity expansion across its global manufacturing network, including a new fill-finish plant in Copenhagen.

Highlights

• Platform created for continued growth and enhanced margins, based on a broadened product range and an exciting pipeline of new products
• Xellia’s focus on R&D resulted in 15 new product filings in 2012
• Expanded their global manufacturing network including a new fill-finish plant in Copenhagen

Regulatory information 
This transaction involved a recommendation of 3i Investments plc, advised by 3i Sweden.